These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8977222)

  • 41. [The T-lymphocyte. A hero or a villain in the drama?].
    Grunewald J; Wigzell H
    Lakartidningen; 1993 Jan; 90(3):149-50, 153. PubMed ID: 8429746
    [No Abstract]   [Full Text] [Related]  

  • 42. [Targeted immunotherapy against interleukin 2 receptors (IL-2R)--an attempt at synthesis].
    Sabliński T; Wasik MA; Tilney NL; Kupiec-Wegliński JW
    Postepy Hig Med Dosw; 1992; 46(3):275-85. PubMed ID: 1293580
    [No Abstract]   [Full Text] [Related]  

  • 43. Targeting interleukin-6 in autoimmune uveitis.
    Mesquida M; Molins B; Llorenç V; de la Maza MS; Adán A
    Autoimmun Rev; 2017 Oct; 16(10):1079-1089. PubMed ID: 28778705
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Analysis of IL-3 receptor using monoclonal antibodies].
    Ohta Y; Sugawara M
    Tanpakushitsu Kakusan Koso; 1988 Sep; 33(11):1819-23. PubMed ID: 3071825
    [No Abstract]   [Full Text] [Related]  

  • 45. Bench to bedside: new approaches to the immunotherapy of uveitic disease.
    Nussenblatt RB
    Int Rev Immunol; 2002; 21(2-3):273-89. PubMed ID: 12424847
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synergism between corticosteroids and Rapamycin for the treatment of intraocular inflammation.
    Roberge FG; Martin DF; Xu D; Chen H; Chan CC
    Ocul Immunol Inflamm; 1995; 3(3):195-202. PubMed ID: 22823241
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of uveitis with recombinant human interleukin-13.
    Roberge FG; de Smet MD; Benichou J; Kriete MF; Raber J; Hakimi J
    Br J Ophthalmol; 1998 Oct; 82(10):1195-8. PubMed ID: 9924310
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lymphokine receptor-directed therapy: a model for immune intervention in leukemia, autoimmunity, and immunodeficiency.
    Waldmann TA
    Clin Immunol Immunopathol; 1991 Nov; 61(2 Pt 2):S37-46. PubMed ID: 1934612
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Evolution of the concepts related to uveitis].
    Witmer R
    Ophtalmologie; 1987; 1(2):127-31. PubMed ID: 3153833
    [No Abstract]   [Full Text] [Related]  

  • 50. [Value of the level of lymphocyte transformation in uveitis].
    Bloch-Michel E; Cartron ; Campinchi R
    Presse Med (1893); 1971 Feb; 79(9):402. PubMed ID: 5546803
    [No Abstract]   [Full Text] [Related]  

  • 51. Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF-α inhibition: a narrative review.
    Gaggiano C; Rigante D; Tosi GM; Vitale A; Frediani B; Grosso S; Fabiani C; Cantarini L
    Clin Rheumatol; 2020 Feb; 39(2):327-337. PubMed ID: 31823144
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program.
    Gold R; Stefoski D; Selmaj K; Havrdova E; Hurst C; Holman J; Tornesi B; Akella S; McCroskery P
    Neurol Ther; 2016 Dec; 5(2):169-182. PubMed ID: 27411694
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunotherapeutic strategies in autoimmune uveitis.
    Papotto PH; Marengo EB; Sardinha LR; Goldberg AC; Rizzo LV
    Autoimmun Rev; 2014 Sep; 13(9):909-16. PubMed ID: 24833504
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biologic agents in experimental autoimmune uveitis.
    Giuliari GP; Sadaka A; Hinkle DM
    Int Ophthalmol; 2014 Feb; 34(1):145-56. PubMed ID: 23494482
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets.
    Bugelski PJ; Martin PL
    Br J Pharmacol; 2012 Jun; 166(3):823-46. PubMed ID: 22168282
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of immune activation by a novel nuclear factor-kappa B inhibitor in HTLV-I-associated neurologic disease.
    Oh U; McCormick MJ; Datta D; Turner RV; Bobb K; Monie DD; Sliskovic DR; Tanaka Y; Zhang J; Meshulam J; Jacobson S
    Blood; 2011 Mar; 117(12):3363-9. PubMed ID: 21212284
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.
    Heiligenhaus A; Thurau S; Hennig M; Grajewski RS; Wildner G
    Graefes Arch Clin Exp Ophthalmol; 2010 Nov; 248(11):1531-51. PubMed ID: 20737162
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibody-based therapy of leukaemia.
    Morris JC; Waldmann TA
    Expert Rev Mol Med; 2009 Sep; 11():e29. PubMed ID: 19788782
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-infectious pediatric uveitis: an update on immunomodulatory management.
    Sharma SM; Dick AD; Ramanan AV
    Paediatr Drugs; 2009; 11(4):229-41. PubMed ID: 19566107
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.
    Yeh S; Wroblewski K; Buggage R; Li Z; Kurup SK; Sen HN; Dahr S; Sran P; Reed GF; Robinson R; Ragheb JA; Waldmann TA; Nussenblatt RB
    J Autoimmun; 2008 Sep; 31(2):91-7. PubMed ID: 18571896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.